Jenniferl Riter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Considerations In Combination Product Risk Management By Susan Neadle, Johnson & Johnson, Inc.; Jennifer L. Riter, West Pharmaceutical Services, Inc.; T. Page McAndrew, West Pharmaceutical Services, Inc. Drug-device combination products are an ever-increasing presence in the pharmaceutical landscape. Benefits include more convenience for patients, lower costs from fewer/eliminated hospital/clinic visits, fewer steps in usage as drug product may not need to be withdrawn from a vial, better safety with automatic needle retraction, and better compliance through connectivity such as smartphone apps. As with any pharmaceutical product, commercial offering requires demonstration of performance and compliance with applicable regulations. This article is a review of select aspects of the webinar, Creating an Effective Combination Products Risk Management Program: Special Considerations for Control and Analytical Testing Strategies Development.

Jenniferl riterSusan neadleJohnson incServices incEffective combination products risk management programAnalytical testing strategies developmentWest pharmaceutical servicesSpecial considerationsAnalytical testing strategiesஜான்சன் இன்க்சேவைகள் இன்க்பயனுள்ள சேர்க்கை ப்ராடக்ட்ஸ் ஆபத்து மேலாண்மை ப்ரோக்ர்யாம்பகுப்பாய்வு சோதனை உத்திகள் வளர்ச்சிமேற்கு மருந்து சேவைகள்பகுப்பாய்வு சோதனை உத்திகள்